These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19670989)

  • 1. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference.
    Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):305-7. PubMed ID: 19670989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Navigating joint HTA, procurement, and fair pricing: evidence-based insights and practical recommendations - A meeting report from ISPOR regional conference in Warsaw, 2019.
    Inotai A; Németh B
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):379-381. PubMed ID: 31159614
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative effectiveness research and healthcare reform: topics of the day.
    DeKoven M; Goldberg E; Powers J
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):395-7. PubMed ID: 21831018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (November 4-6, 2019 - Copenhagen, Denmark).
    Kibble A
    Drugs Today (Barc); 2019 Nov; 55(11):713-718. PubMed ID: 31840686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abstracts of the ISPOR (International Society for Pharmacoeconomics and Outcomes Research) Fourteenth Annual International Meeting. May 16-20, 2009. Orlando, Florida, USA.
    Value Health; 2009 May; 12(3):A1-203. PubMed ID: 19392734
    [No Abstract]   [Full Text] [Related]  

  • 7. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI.
    Shi L; Hodges M; Drummond M; Ahn J; Li SC; Hu S; Augustovski F; Hay JW; Smeeding J
    Value Health; 2010; 13(1):28-33. PubMed ID: 19883403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III.
    Mansley EC; Carroll NV; Chen KS; Shah ND; Piech CT; Hay JW; Smeeding J
    Value Health; 2010; 13(1):14-7. PubMed ID: 19883404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International Society for Pharmacoeconomics and Outcomes Research (ISPOR)4th Annual European Conference. 11-13 November 2001. Cannes, France. Abstracts.
    Value Health; 2001; 4(6):401-540. PubMed ID: 11727724
    [No Abstract]   [Full Text] [Related]  

  • 11. Proceedings of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Second Latin America Conference. September 2009. Brazil.
    Value Health; 2011; 14(5 Suppl 1):S1-150. PubMed ID: 21998840
    [No Abstract]   [Full Text] [Related]  

  • 12. 11th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR): Athens, Greece, 8-11 November 2008.
    Appl Health Econ Health Policy; 2008; 6(2-3):163-71. PubMed ID: 19231909
    [No Abstract]   [Full Text] [Related]  

  • 13. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 7th Annual International Meeting. May 19-22, 2002. Arlington, Virginia, USA. Abstracts.
    Value Health; 2002; 5(3):117-294. PubMed ID: 12010559
    [No Abstract]   [Full Text] [Related]  

  • 14. Abstracts of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 9th Annual International Meeting. May 16-19, 2004, Arlington, Virginia, USA.
    Value Health; 2004; 7(3):219-393. PubMed ID: 15279015
    [No Abstract]   [Full Text] [Related]  

  • 15. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 6th Annual International Meeting. May 20-23, 2001. Arlington, Virginia, USA. Abstracts.
    Value Health; 2001; 4(2):47-209. PubMed ID: 11700642
    [No Abstract]   [Full Text] [Related]  

  • 16. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II.
    Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J
    Value Health; 2010; 13(1):8-13. PubMed ID: 19883405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting (May 17-20, 2021 - Virtual Meeting).
    Kibble A
    Drugs Today (Barc); 2021 Aug; 57(8):519-525. PubMed ID: 34405209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.
    Garrison LP; Neumann PJ; Erickson P; Marshall D; Mullins CD
    Value Health; 2007; 10(5):326-35. PubMed ID: 17888097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making: an interview with Marc Berger.
    Berger ML
    J Comp Eff Res; 2018 Jan; 7(1):11-13. PubMed ID: 29052427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The 2nd Annual Conference of the Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel), September 2008].
    Tal O
    Harefuah; 2009 Aug; 148(8):554-6. PubMed ID: 19899262
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.